Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNFerade plus radiation in metastatic melanoma
NCT00261404Phase 2Completed
- Sponsor
- GenVec
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of golnerminogene pradenovec in melanoma, sponsored by GenVec. Status: completed.
02
Drugs
golnerminogene pradenovec
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00261404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00261404.